Drug Type Bispecific killer cell engager (BiKE) |
Synonyms |
Target |
Mechanism CD16a modulators(Low affinity immunoglobulin gamma Fc region receptor III-A modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization Navrogen, Inc.Startup |
Active Organization Navrogen, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
COVID-19 | Phase 2 | US | Navrogen, Inc.Startup | 13 Sep 2021 |
Hematologic Neoplasms | Preclinical | US | Navrogen, Inc.Startup | 29 Mar 2022 |
Solid tumor | Preclinical | US | Navrogen, Inc.Startup | 29 Mar 2022 |